Endoglin interacts with VEGFR2 to promote angiogenesis

Area of Science:

• Molecular biology
• Cell biology
• Cancer research

Background:

• Endoglin is a TGF-β coreceptor crucial for vascular development and tumor angiogenesis.
• The precise mechanism of endoglin's role in angiogenesis, particularly tip cell formation, is not fully understood.

Purpose of the Study:

• To elucidate the mechanism by which endoglin regulates VEGF-driven angiogenesis.
• To investigate the therapeutic potential of combining anti-endoglin and anti-VEGF agents.

Main Methods:

• Investigated endoglin's interaction with VEGF receptor (VEGFR)-2 in endothelial cells.
• Utilized endoglin mutants to assess VEGFR2 stabilization and tip cell formation.
• Evaluated the efficacy of TRC105 (anti-endoglin mAb) and bevacizumab (anti-VEGF-A mAb) in vitro and in a murine tumor model.

Main Results:

• Endoglin promotes VEGF-induced tip cell formation by interacting with VEGFR2.
• This interaction stabilizes VEGFR2 on the cell surface, preventing its degradation.
• Combined TRC105 and bevacizumab inhibited VEGF signaling, tip cell formation, tumor growth, metastasis, and angiogenesis in vivo.

Conclusions:

• Endoglin plays a novel role in initiating and regulating VEGF-driven angiogenesis through VEGFR2 interaction.
• Combination therapy with anti-endoglin and anti-VEGF antibodies shows promise for cancer treatment by targeting angiogenesis.